Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.37
HSP's Cash to Debt is ranked lower than
78% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. HSP: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
HSP' s 10-Year Cash to Debt Range
Min: 0.08  Med: 0.38 Max: N/A
Current: 0.37
Equity to Asset 0.53
HSP's Equity to Asset is ranked lower than
64% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HSP: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
HSP' s 10-Year Equity to Asset Range
Min: 0.28  Med: 0.48 Max: 0.65
Current: 0.53
0.28
0.65
Interest Coverage 6.04
HSP's Interest Coverage is ranked lower than
85% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. HSP: 6.04 )
Ranked among companies with meaningful Interest Coverage only.
HSP' s 10-Year Interest Coverage Range
Min: 0.19  Med: 5.59 Max: 9999.99
Current: 6.04
0.19
9999.99
F-Score: 7
Z-Score: 4.73
M-Score: -2.62
WACC vs ROIC
9.26%
8.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.90
HSP's Operating margin (%) is ranked higher than
59% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. HSP: 10.90 )
Ranked among companies with meaningful Operating margin (%) only.
HSP' s 10-Year Operating margin (%) Range
Min: 0.41  Med: 12.89 Max: 16.17
Current: 10.9
0.41
16.17
Net-margin (%) 7.43
HSP's Net-margin (%) is ranked higher than
56% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. HSP: 7.43 )
Ranked among companies with meaningful Net-margin (%) only.
HSP' s 10-Year Net-margin (%) Range
Min: -0.23  Med: 8.91 Max: 11.4
Current: 7.43
-0.23
11.4
ROE (%) 10.35
HSP's ROE (%) is ranked higher than
61% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. HSP: 10.35 )
Ranked among companies with meaningful ROE (%) only.
HSP' s 10-Year ROE (%) Range
Min: -0.31  Med: 17.66 Max: 24.74
Current: 10.35
-0.31
24.74
ROA (%) 5.28
HSP's ROA (%) is ranked higher than
59% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HSP: 5.28 )
Ranked among companies with meaningful ROA (%) only.
HSP' s 10-Year ROA (%) Range
Min: -0.16  Med: 6.32 Max: 13.13
Current: 5.28
-0.16
13.13
ROC (Joel Greenblatt) (%) 18.06
HSP's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. HSP: 18.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1.49  Med: 23.30 Max: 53.84
Current: 18.06
-1.49
53.84
Revenue Growth (3Y)(%) 2.20
HSP's Revenue Growth (3Y)(%) is ranked lower than
63% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. HSP: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.9  Med: 2.20 Max: 12.4
Current: 2.2
-0.9
12.4
EBITDA Growth (3Y)(%) 29.60
HSP's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. HSP: 29.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.3  Med: -0.50 Max: 29.6
Current: 29.6
-32.3
29.6
» HSP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

HSP Guru Trades in Q2 2014

Mario Gabelli 204,370 sh (+32.91%)
Jim Simons 182,900 sh (+20.49%)
Vanguard Health Care Fund 8,375,170 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Jeff Auxier 181,463 sh (-11.71%)
John Rogers 3,130,809 sh (-24.15%)
Paul Tudor Jones 7,700 sh (-28.70%)
» More
Q3 2014

HSP Guru Trades in Q3 2014

Joel Greenblatt 313,242 sh (New)
Paul Tudor Jones 24,894 sh (+223.30%)
Jim Simons 323,100 sh (+76.65%)
Mario Gabelli 254,870 sh (+24.71%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
Vanguard Health Care Fund 8,375,170 sh (unchged)
John Rogers 2,433,369 sh (-22.28%)
Jeff Auxier 127,307 sh (-29.84%)
» More
Q4 2014

HSP Guru Trades in Q4 2014

Jim Simons 631,695 sh (+95.51%)
Mario Gabelli 352,370 sh (+38.25%)
Michael Price 400,000 sh (unchged)
Robert Bruce 10,000 sh (unchged)
Joel Greenblatt Sold Out
Jeff Auxier 126,907 sh (-0.31%)
Vanguard Health Care Fund 7,966,970 sh (-4.87%)
John Rogers 2,311,309 sh (-5.02%)
Paul Tudor Jones 19,798 sh (-20.47%)
» More
Q1 2015

HSP Guru Trades in Q1 2015

Jeremy Grantham 657,484 sh (New)
Mario Gabelli 834,303 sh (+136.77%)
Robert Bruce 10,000 sh (unchged)
Michael Price 400,000 sh (unchged)
John Rogers Sold Out
Vanguard Health Care Fund Sold Out
Jeff Auxier 57,665 sh (-54.56%)
Paul Tudor Jones 5,652 sh (-71.45%)
Jim Simons 93,800 sh (-85.15%)
» More
» Details

Insider Trades

Latest Guru Trades with HSP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 45.17
HSP's P/E(ttm) is ranked lower than
63% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. HSP: 45.17 )
Ranked among companies with meaningful P/E(ttm) only.
HSP' s 10-Year P/E(ttm) Range
Min: 8.48  Med: 25.31 Max: 133.97
Current: 45.17
8.48
133.97
Forward P/E 26.18
HSP's Forward P/E is ranked lower than
56% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. HSP: 26.18 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 45.10
HSP's PE(NRI) is ranked lower than
62% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. HSP: 45.10 )
Ranked among companies with meaningful PE(NRI) only.
HSP' s 10-Year PE(NRI) Range
Min: 8.48  Med: 25.27 Max: 135
Current: 45.1
8.48
135
P/B 4.49
HSP's P/B is ranked lower than
59% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. HSP: 4.49 )
Ranked among companies with meaningful P/B only.
HSP' s 10-Year P/B Range
Min: 1.52  Med: 3.02 Max: 5.83
Current: 4.49
1.52
5.83
P/S 3.36
HSP's P/S is ranked higher than
51% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. HSP: 3.36 )
Ranked among companies with meaningful P/S only.
HSP' s 10-Year P/S Range
Min: 0.99  Med: 1.99 Max: 3.36
Current: 3.36
0.99
3.36
PFCF 159.63
HSP's PFCF is ranked lower than
83% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. HSP: 159.63 )
Ranked among companies with meaningful PFCF only.
HSP' s 10-Year PFCF Range
Min: 8.32  Med: 28.68 Max: 203.78
Current: 159.63
8.32
203.78
POCF 28.18
HSP's POCF is ranked higher than
52% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. HSP: 28.18 )
Ranked among companies with meaningful POCF only.
HSP' s 10-Year POCF Range
Min: 5.95  Med: 13.23 Max: 50.76
Current: 28.18
5.95
50.76
EV-to-EBIT 33.07
HSP's EV-to-EBIT is ranked lower than
60% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. HSP: 33.07 )
Ranked among companies with meaningful EV-to-EBIT only.
HSP' s 10-Year EV-to-EBIT Range
Min: -1403.5  Med: 18.60 Max: 508.2
Current: 33.07
-1403.5
508.2
Shiller P/E 83.51
HSP's Shiller P/E is ranked lower than
81% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. HSP: 83.51 )
Ranked among companies with meaningful Shiller P/E only.
HSP' s 10-Year Shiller P/E Range
Min: 12.55  Med: 28.40 Max: 83.58
Current: 83.51
12.55
83.58
Current Ratio 2.48
HSP's Current Ratio is ranked higher than
53% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. HSP: 2.48 )
Ranked among companies with meaningful Current Ratio only.
HSP' s 10-Year Current Ratio Range
Min: 1.61  Med: 2.50 Max: 3.03
Current: 2.48
1.61
3.03
Quick Ratio 1.43
HSP's Quick Ratio is ranked lower than
56% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. HSP: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
HSP' s 10-Year Quick Ratio Range
Min: 1  Med: 1.47 Max: 2.04
Current: 1.43
1
2.04
Days Inventory 148.96
HSP's Days Inventory is ranked lower than
66% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. HSP: 148.96 )
Ranked among companies with meaningful Days Inventory only.
HSP' s 10-Year Days Inventory Range
Min: 47.38  Med: 119.45 Max: 139.51
Current: 148.96
47.38
139.51
Days Sales Outstanding 47.40
HSP's Days Sales Outstanding is ranked higher than
71% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. HSP: 47.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSP' s 10-Year Days Sales Outstanding Range
Min: 43.91  Med: 49.22 Max: 59.38
Current: 47.4
43.91
59.38

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.93
HSP's Price/Tangible Book is ranked lower than
68% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. HSP: 6.93 )
Ranked among companies with meaningful Price/Tangible Book only.
HSP' s 10-Year Price/Tangible Book Range
Min: 3.04  Med: 5.63 Max: 76.38
Current: 6.93
3.04
76.38
Price/Projected FCF 3.51
HSP's Price/Projected FCF is ranked lower than
52% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. HSP: 3.51 )
Ranked among companies with meaningful Price/Projected FCF only.
HSP' s 10-Year Price/Projected FCF Range
Min: 0.91  Med: 1.36 Max: 3.45
Current: 3.51
0.91
3.45
Price/Median PS Value 1.69
HSP's Price/Median PS Value is ranked lower than
65% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. HSP: 1.69 )
Ranked among companies with meaningful Price/Median PS Value only.
HSP' s 10-Year Price/Median PS Value Range
Min: 0.6  Med: 1.00 Max: 1.66
Current: 1.69
0.6
1.66
Price/Graham Number 3.74
HSP's Price/Graham Number is ranked lower than
66% of the 366 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. HSP: 3.74 )
Ranked among companies with meaningful Price/Graham Number only.
HSP' s 10-Year Price/Graham Number Range
Min: 1.85  Med: 2.69 Max: 9.99
Current: 3.74
1.85
9.99
Earnings Yield (Greenblatt) (%) 3.00
HSP's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. HSP: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 4.90 Max: 10
Current: 3
0.2
10
Forward Rate of Return (Yacktman) (%) -4.86
HSP's Forward Rate of Return (Yacktman) (%) is ranked lower than
74% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. HSP: -4.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSP' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -1.6  Med: 9.40 Max: 18.4
Current: -4.86
-1.6
18.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:HOS.Germany,
Hospira Inc was incorporated in Delaware on September 16, 2003. The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.
» More Articles for HSP

Headlines

Articles On GuruFocus.com
Skyworks Solutions Tops Highest-Performing S&P 500 Stocks Jun 05 2015 
John Rogers' Ariel Fund Q1 2015 Commentary Apr 16 2015 
Weekly 52-Week Highs Highlight: SIAL, GIS, TJX, HSP Mar 30 2015 
Hospira’s Q4 Earnings Were Bright, Though Acquisition Is In The Cards Feb 19 2015 
Analysts Weigh in on Pfizer Following Acquisition Announcement of Hospira Feb 06 2015 
Feeling Good With This Med Company Jan 20 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 

More From Other Websites
Hospira (HSP) Beats on Q2 Earnings Driven by Strong Sales - Analyst Blog Jul 29 2015
Hikma Pharmaceuticals Plc: Strong price momentum but will it sustain? Jul 29 2015
Hospira (HSP) Beats on Q2 Earnings, Revenues In Line - Tale of the Tape Jul 29 2015
Hospira Reports Second-Quarter 2015 Results Jul 29 2015
Hospira beats 2Q profit forecasts Jul 29 2015
Hospira beats 2Q profit forecasts Jul 29 2015
HOSPIRA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2015
7:33 am Hospira beats by $0.05, reports revs in-line Jul 29 2015
Hospira Reports Second-Quarter 2015 Results Jul 29 2015
Q2 2015 Hospira Inc Earnings Release - Before Market Open Jul 29 2015
Pfizer (PFE) Earnings Report: Q2 2015 Conference Call Transcript Jul 28 2015
Pfizer Beats on Q2 Earnings and Revenues, Revises Outlook - Analyst Blog Jul 28 2015
Options traders bet against Pfizer Jul 27 2015
What's in Store for Hospira (HSP) this Earnings Season? - Analyst Blog Jul 27 2015
Street Talk: AVG under the radar Jul 23 2015
Hospira (HSP) Launches Generic Angiomax in the U.S. - Analyst Blog Jul 17 2015
Hospira Announces U.S. Launch of Generic Bivalirudin for Injection Jul 16 2015
Hospira Announces U.S. Launch of Generic Bivalirudin for Injection Jul 16 2015
Hospira to Announce Second-Quarter 2015 Results on July 29, 2015 Jul 15 2015
Hospira to Announce Second-Quarter 2015 Results on July 29, 2015 Jul 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK